Abstract
Between 2%-6% of endometrial cancer (EC) cases are attributable to Lynch syndrome (LS). Although universal tumor screening for LS among patients with EC is recommended by professional societies, implementation remains suboptimal. Our objective is to compare the relative performance, costs, and efficiency of different LS screening protocols among newly diagnosed EC patients from a U.S. healthcare system perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have